Case reports in oncology · 2026
Gastric Cancer Treated with 5-Fluorouracil following Discontinuation of Adjuvant S1 plus Docetaxel and Capecitabine plus Oxaliplatin due to Drug-Induced Acute Pancreatitis: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takamori Yumi, Aoki Yu, Miyake Hiroaki, Amano Yumi, Tanuma Kota, Nakazawa Atsushi, Hoshino Shota, Toriumi Fumiki, Hirose Shigemichi, Funakoshi Shinsuke
Аннотация
INTRODUCTION: Drug-induced acute pancreatitis (DIAP) is a rare cause of acute pancreatitis, accounting for approximately 3-5% of cases, and reports of chemotherapy-induced pancreatitis remain limited.
CASE PRESENTATION: Herein, we present the case of a 68-year-old man who developed DIAP during adjuvant chemotherapy with S-1 plus docetaxel and later with capecitabine plus oxaliplatin following surgery for gastric cancer. A drug-induced lymphocyte stimulation test (DLST) was conducted to identify the suspected agents, yielding positive results for S-1 and capecitabine, whereas docetaxel and oxaliplatin were negative. Unexpectedly, the DLST result for 5-fluorouracil was negative. Based on these findings, adjuvant chemotherapy was switched to 5-fluorouracil plus leucovorin, which was successfully continued without recurrence of pancreatitis. Shortly thereafter, the patient was diagnosed with recurrent gastric cancer. However, palliative chemotherapy with a 5-fluorouracil-based regimen was safely continued.
CONCLUSION: Although DIAP can be fatal, the DLST may help identify the suspected causative drug and contribute to decision-making in important clinical situations such as cancer treatment.
CASE PRESENTATION: Herein, we present the case of a 68-year-old man who developed DIAP during adjuvant chemotherapy with S-1 plus docetaxel and later with capecitabine plus oxaliplatin following surgery for gastric cancer. A drug-induced lymphocyte stimulation test (DLST) was conducted to identify the suspected agents, yielding positive results for S-1 and capecitabine, whereas docetaxel and oxaliplatin were negative. Unexpectedly, the DLST result for 5-fluorouracil was negative. Based on these findings, adjuvant chemotherapy was switched to 5-fluorouracil plus leucovorin, which was successfully continued without recurrence of pancreatitis. Shortly thereafter, the patient was diagnosed with recurrent gastric cancer. However, palliative chemotherapy with a 5-fluorouracil-based regimen was safely continued.
CONCLUSION: Although DIAP can be fatal, the DLST may help identify the suspected causative drug and contribute to decision-making in important clinical situations such as cancer treatment.